title: Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
abstract: BACKGROUND
  Medical or surgical castration is effective in advanced prostate cancer but with profound side-effects, particularly on sexual function. Effective, less toxic therapies are needed. This study examined whether the addition of finasteride to high-dose bicalutamide enhanced disease control, as measured by additional decreases in serum prostate-specific antigen (PSA).
  
  
  METHODS
  Forty-one patients with advanced prostate cancer received bicalutamide (150 mg/day). Finasteride (5 mg/day) was added at first PSA nadir. Serum PSA was measured every 2 weeks until disease progression. Questionnaires were administered to assess sexual function.
  
  
  RESULTS
  Median follow-up is 3.9 years. At the first PSA nadir, median decrease in PSA from baseline was 96.5%. Thirty of 41 patients (73%) achieved a second PSA nadir and median decrease of 98.5% from baseline. Median time to each nadir was 3.7 and 5.8 weeks, respectively. Median time to treatment failure was 21.3 months. Toxicities were minor, including gynecomastia. Seventeen of 29 (59%) and 12 of 24 (50%) men had normal sex drive at baseline and at second PSA nadir, respectively. One-third of men had spontaneous erection at both time points.
  
  
  CONCLUSIONS
  Finasteride provides additional intracellular androgen blockade when added to bicalutamide. Duration of control is comparable to castration, with preserved sexual function in some patients.
authors.affiliation: Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
authors.forename: M-H
authors.initials: MH
authors.lastname: Tay
authors.forename: D S
authors.initials: DS
authors.lastname: Kaufman
authors.forename: M M
authors.initials: MM
authors.lastname: Regan
authors.forename: S B
authors.initials: SB
authors.lastname: Leibowitz
authors.forename: D J
authors.initials: DJ
authors.lastname: George
authors.forename: P G
authors.initials: PG
authors.lastname: Febbo
authors.forename: J
authors.initials: J
authors.lastname: Manola
authors.forename: M R
authors.initials: MR
authors.lastname: Smith
authors.forename: I D
authors.initials: ID
authors.lastname: Kaplan
authors.forename: P W
authors.initials: PW
authors.lastname: Kantoff
authors.forename: W K
authors.initials: WK
authors.lastname: Oh
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000813:Anilides / Q000008:administration & dosage* / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000139:chemically induced; D018120:Finasteride / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009570:Nitriles; D010865:Pilot Projects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014105:Tosyl Compounds
chemical_list: D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D018120:Finasteride; C053541:bicalutamide; D017430:Prostate-Specific Antigen